Coumestrol as an Effective Dietary Supplement: Comprehensive Experimental Evidence From In Vitro Studies and Animal Models of Human Disease

Introduction of Dietary Phytoestrogens- Phytoestrogens are plant-derived polyphenolic non-steroidal compounds that exhibit Estrogen-like biological effects. The estrogenic characteristics of specific plants have been acknowledged for over fifty years. During the mid-1940s, an infertility condition in sheep was linked to the consumption of clover that had elevated amounts of the isoflavones formononetin and biochanin A^[1],[2]. Lately, a growing body of epidemiological and experimental research indicates that diets high in phytoestrogens might offer protective benefits against Estrogen-related issues, including menopausal symptoms ^[3], as well as Estrogen-associated diseases like prostate ^[4] and breast cancers ^[5], osteoporosis ^[6], and cardiovascular diseases (CVD^)[7]. Nonetheless, worries have been expressed regarding the possible risks associated with ingesting elevated amounts of these substances ^[8]. As a result, phytoestrogens are presently being actively explored for their impact on human health. Thus, a prior review in this journal regarding the in vitro assessment techniques of phytoestrogens will be enhanced ^[9]. Humans encounter various xenobiotic estrogen-mimicking chemicals through the food chain, including DDY, polychlorinated biphenyls (PCBs), and diethyl stilbestrol(DE3). Lately, considerable focus has been placed on these xenoestrogens due to their lasting impacts on the endocrine system. Moreover, pharmaceutical estrogens like ethinylestradiol can be categorized as synthetic estrogen analogs^{. [10]}

Classification scheme of dietary Estrogens.

Estrogen Receptors and Selective Estrogen Receptor Modulators (SERMs)

Estrogens play crucial roles in regulating numerous target tissues, including both male and female reproductive systems, bone tissue, as well as the cardiovascular and central nervous systems. Estrogens are utilized for preventing and managing postmenopausal symptoms and as contraceptives, whereas Estrogen antagonists are employed for treating hormone-dependent breast cancers^{. [11]} Coumestrol is a natural compound classified among the phytochemicals referred to as coumestans. In 1957, E. M. Bickoff first recognized coumestrol as a compound exhibiting estrogenic properties in alfalfa and ladino clover. Coumestrol is a plant-derived Estrogen, replicating the biological function of estrogens. Phytoestrogens can cross cell membranes owing to their small molecular size and stable configuration, allowing them to interact with cellular enzymes and receptors. Coumestrol binds to ERα and ERβ with comparable affinity to estradiol (94% and 185% relative binding affinity of estradiol at ERα and ERβ, respectively), even though its estrogenic potency at both receptors is significantly lower than that of estradiol. Nevertheless, coumestrol exhibits estrogenic activity that is 30 to 100 times more potent than that of isoflavones.^[12] The molecular structure of Coumestrol aligns its two hydroxy groups in the same arrangement as the hydroxy groups in estradiol, enabling it to block the function of aromatase and 3α-hydroxysteroid dehydrogenase. ^[13] These enzymes play a role in the production of steroid hormones, and their inhibition disrupts hormone metabolism ^[14]

Naturally occurring selective Estrogen receptor modulators (SERMs) represent a promising therapeutic alternative.

Preclinical evidence suggests Coumestrol may:

• Improve bone remodelling
• Reduce oxidative stress
• Modulate inflammatory cytokines
• Improve lipid metabolism
• Enhance glucose tolerance

The consumption of high levels of phytoestrogens, as may occur with botanical dietary supplements, should probably be approached cautiously or discouraged for patients with cancer or at elevated risk for ER+ cancer. Additional research, both basic and clinical, is required to understand the full impact of phytoestrogens on cancer prevention, promotion, progression, and treatment. ^[15-16]

MATERIALS AND METHODOLOGY-

The experimental study was designed using a randomized controlled animal model comprising five groups: vehicle control, low-dose Coumestrol, mid-dose Coumestrol, high-dose Coumestrol, and a positive control group where applicable.

1. Vehicle control (No Coumestrol)
2. Low-dose Coumestrol (dietary exposure equivalent)
3. Mid-dose Coumestrol
4. High-dose Coumestrol (safety margin)
5. Positive control (Metabolic modulator)

Sample size was determined based on statistical power calculations considering primary endpoints such as fasting glucose levels and pharmacokinetic parameters, with a typical group size of 6–10 animals. Animals were randomly allocated to different groups, and outcome assessments including biochemical and histopathological analyses were performed in a blinded manner to minimize bias.

Drugs and Chemicals: All reagents were of analytical grade and freshly prepared. Coumestrol was used as the test compound, with methanol and acetonitrile for analysis. Other materials included DMSO, PBS, normal saline, biochemical assay kits (ALT, AST, ALP, creatinine, urea, glucose, lipid profile), oxidative stress kits, hematology reagents, and histological supplies.

Experimental Animals: Adult male Wistar rats (200–250 g) were housed in polypropylene cages under standard conditions with ad libitum food and water. The study was approved by the IAEC as per CPCSEA guidelines (Protocol No.: 1888/PO/Re/S/16/CCSEA/2025/03).

Acute Toxicity Study: Acute toxicity was evaluated according to OECD guidelines using the acute toxic class method. Animals (n = 3 per step, single sex) were dosed sequentially, and toxicity was assessed based on mortality and clinical signs, allowing classification without precise LD₅₀ determination^{. [17-18]}.

Dose Administration: The test compound was administered orally via gavage. Animals were fasted prior to dosing, weighed, and monitored post-administration. Dosing decisions were adjusted stepwise based on observed toxicity. Coumestrol was administered via the oral route, which is most relevant for dietary supplementation. For chronic exposure, feed admixture was preferred, while oral gavage was utilized for single-dose pharmacokinetic studies. Dose selection was based on literature evidence, with low dose representing human equivalent exposure, mid dose set at 3–5 times the low dose, and high dose representing a safety margin of up to 10 times the low dose^{. [19]}.

STUDY DESIGN:

The study included both a pilot single-dose pharmacokinetic phase and a repeated-dose phase^{. [20-22]}. The pharmacokinetic study involved a single oral administration followed by serial blood sampling over 24–72 hours, while the repeated-dose study involved daily dosing for 14–28 days (subacute) or up to 90 days (Subchronic), depending on study objectives. Animals had ad libitum access to food and water except during fasting conditions required for specific metabolic assessments^{. [23-26]}.

1. For pharmacokinetic evaluation, blood samples were collected at predefined time points including pre-dose and multiple post-dose intervals to determine parameters such as Cmax, Tmax, AUC, and half-life using non-compartmental analysis.
2. In repeated-dose studies, baseline measurements such as body weight, food intake, and biochemical parameters were recorded prior to treatment. Interim blood sampling was conducted periodically for clinical chemistry analysis.

Blood and urine collection: Blood samples were collected before (baseline) isoflavone administration and 1, 2, 3, 4.5, 6, 8, 10, 12, 24, and 48 h after the dose. Blood was obtained by an indwelling cannula for samples up to 12 h and thereafter by venipuncture. Plasma was collected after centrifugation at 1500 g for 10 min at 4 °C. Aliquots were stored at 80 °C until analysis ^[27]. During the intervention period, urine was collected before and 0 – 6, 6 –12, and 12–24 h after the intake of the Dietary supplements.

• Biochemical assessments included liver function tests (ALT, AST, bilirubin, alkaline phosphatase), renal markers (creatinine and blood urea nitrogen), lipid profile (total cholesterol, HDL, LDL, triglycerides), and glucose metabolism indicators including fasting glucose and insulin levels with calculation of insulin resistance indices. Haematological analysis included complete blood count parameters such as haemoglobin, white blood cell count, and platelet count.
• Metabolic evaluations involved monitoring of body weight, food intake, and performance of glucose or insulin tolerance tests under standardized conditions.

RESULT & DISCUSSION-

Following oral administration of Coumestrol, plasma concentration–time profiles demonstrated a clear dose-dependent increase in systemic exposure. The maximum plasma concentration (Cmax) increased proportionally with dose, indicating efficient absorption. The time to reach peak concentration (Tmax) was observed within 1–3 hours across all treatment groups, suggesting rapid oral absorption. The elimination half-life (t½) of Coumestrol indicated moderate clearance, with slightly prolonged values at higher doses, possibly due to saturation of metabolic pathways. The area under the plasma concentration–time curve (AUC) increased in a dose-dependent manner, confirming enhanced systemic exposure with increasing doses. Overall, the pharmacokinetic profile of Coumestrol showed predictable absorption, distribution, and elimination characteristics without evidence of abnormal accumulation at the studied dose levels.

Table No.1 Preclinical Evaluation of Coumestrol in a Rodent Model

Table 2: Effect of Coumestrol on Primary Biochemical Parameters (Mean ± SD, n = 6)

Table 3: Effect of Coumestrol on Secondary Parameters (Mean ± SD, n = 6)